Dose–response associations of intermittent lifestyle physical activity micropatterns and incident type 2 diabetes
Chong KH, Ahmadi MN, Biswas RK, et al.
Diabetes Care. Pub. online 28 Apr 2026.
Leggi
Breaking news
Evolocumab to reduce first major cardiovascular events in patients without known significant atherosclerosis and with diabetes results from the VESALIUS-CV trial
Marston NA, Bohula EA, Bhatia AK, et al.
JAMA. Pub. online 28 Mar 2026.
Leggi
Adipose as a driver, not a bystander: a modern synthesis of obesity‐related erectile dysfunction
Sailis AB, Mat Noh MA
Diabetes Obes Metab. Pub. online 27 Apr 2026.
Leggi
FDA – Drug Safety-related Labeling Changes (SrLC)
20 aprile 2026
Leggi
EMA – New medicine to reduce triglycerides in adults with familial chylomicronaemia syndrome
24 aprile 2026
Leggi
Sex differences in glycemic outcomes: a systematic review and meta-analysis of diabetes treatments
Liu C, Mujahid O, Beneyto A, et al.
BMJ Open Diabetes Res Care. Pub. online 22 Apr 2026.
Leggi
Cardiovascular outcome trials (CVOTs) in cardiorenal metabolic medicine: a decade of transformative progress (2016-2026)
Wen S, Wang C, Xu Z, et al.
Cardiovasc Diabetol. Pub. online 24 Apr 2026.
Leggi
Low uptake and disparities in therapeutic inertia of cardiorenal protective diabetes medications for patients with type 2 diabetes and above-target hemoglobin A1c
German J, Huang WA, Brucker A, et al.
BMJ Open Diabetes Res Care. Pub. online 22 Apr 2026.
Leggi
Implementation of sodium-glucose co-transporter 2 inhibitors use in patients with heart failure across the ejection fraction: data from the Swedish heart failure registry
Ferrannini G, Musella F, Benson L, et al.
Eur Heart J Qual Care Clin Outcomes. Pub. online 19 Apr 2026.
Leggi
Feasibility of using OGTT 1-h PG as a diagnostic criterion for diabetes and pre-diabetes
Chen L, Bian B, Ran H, et al.
BMJ Open Diabetes Res Care. Pub. online 22 Apr 2026.
Leggi